1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and ...

1. Etiologies and epidemiology2. Staging and local/regional considerations3. Systemic Therapy4. Differences in immune checkpoint sensitivity by etiologyCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, He...

1. Stage II Disease2. Overview of BEP, EP, VIP3. Advanced, refractory disease4. Survivorship considerationsCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principl...

1. Background, work up2. Staging of seminoma and NSGCT3. Young Adult/Adolescent Oncology4. Management of Stage I Disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Can...

1. Historical Approach (cytoreduction, IFN-a, sunitinib2. Prognostic risk scores3. Evidence for modern doublet regimens4. Later line therapyCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and R...

1. Risk Factors and Presentation2. Staging and Paraneoplastic syndromes3. Localized Therapy Options and Considerations4. Evidence and Limitations for Adjuvant Systemic Therapy CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and St...

1. Immunohistochemistry of urothelial cancer2. History of systemic therapy in advanced and metastatic disease3. Pembrolizumab and Enfortumab Vedotin4. Approach to second line therapy and beyondCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawr...

1. Etymology, presentation, and work-up of bladder/urothelial cancer2. Role of perioperative systemic therapy3. Tri-modality therapy (bladder sparing approach)4. Considerations for upper tract urothelial cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T....

1. Clinical presentation and work-up2. Intestinal and pancreatobiliary subtypes3. Role of perioperative therapy4. Considerations for metastatic diseaseCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, He...

1. On continuation of ADT and ARAT switch2. Systemic therapy options after progression3. Improper mandated crossover4. PARP inhibitors in prostate cancerCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, ...

1. The chemotherapy revolution in prostate cancer2. Role of ARATs in earlier disease states3. Triple therapy (chemotherapy, ADT, and ARAT)4. Considerations for frailer patients with indolent disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S....

1. Physiology, efficacy and toxicities of androgen deprivation2. Evidence for adjuvant intervention after definitive surgery or radiation3. Role of abiraterone in high-risk localized prostate cancer4. Limited evidence to support definitive salvage approachCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local t...

1. Background and presentation of prostate Cancer2. Evidence behind PSA screening and hallmarks of a screening test3. Staging and risk stratification of Localized Disease4. Management options and the ProtecT TrialCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Th...

1. Role for definitive chemotherapy and radiation2. Controversy on induction chemotherapy3. Considerations for nasopharyngeal cancer4. Approach to metastatic HNSCCCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devit...

1. Anatomy, diagnostic work-up and staging2. Field cancerization3. Indications for adjuvant concurrent chemoradiation4. Evidence to support weekly cisplatin with concurrent radiationCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven ...

1. Presentation, and considerations for regional mesothelioma2. Systemic therapy options for advanced mesothelioma3. Corticosteroids for pemetrexed, paclitaxel and docetaxel4. A quick review on considerations for LCNEC CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent ...

1. Background on SCLC2. Approach to treatment by stage3. Emerging discussion on prophylactic cranial irradiation4. Brief review of basket and umbrella trialsCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hel...

1. Refresher on T+N staging for Stage III2. Evidence for concurrent chemoradiation3. PACIFIC Trial4. Encourage cessation regardless of stage of Lung Cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita,...

1. Background on adjuvant EGFR therapy2. Discussion of initial and updated results3. Hazard Ratios and Context4. When crossover and access limit generalizabilityCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita,...

1. Considerations with surgery, radiation, rate of relapse2. Adjuvant chemotherapy3. Adjuvant immune checkpoint inhibition4. Emerging neoadjuvant trial CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hel...